Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

Last updated: March 15, 2020
Sponsor: Stem Cells Arabia
Overall Status: Active - Recruiting

Phase

1

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04313322
COVID-19
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.

Eligibility Criteria

Inclusion

Inclusion Criteria: COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.

Exclusion

Exclusion Criteria:

  • Participants in other clinical trials

  • patients with malignant tumors

  • pregnant and lactating women

  • co-infection with other infectious viruses or bacteria

  • History of several allergies

  • Patients with history of pulmonary embolism

  • any liver or kidney diseases

  • HIV positive patients

  • Considered by researchers to be not suitable to participate in this clinical trial

  • Chronic heart failure with ejection fraction less than 30%.

Study Design

Total Participants: 5
Study Start date:
March 16, 2020
Estimated Completion Date:
September 30, 2020

Study Description

COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.

Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.

Connect with a study center

  • Stem Cells Arabia

    Amman, 11953
    Jordan

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.